Posted by: fuadelhibri on: April 13, 2011
2010 revenues of $286.2 million 2010 net income of $51.7 million, or $1.63 per share, representing ninth consecutive year of profitability 2010 cash, investments and accounts receivable balance of $210.4 million 2011 forecast reaffirmed: total revenues of $320 to $340 million and net income of $35 to $45 million Emergent BioSolutions Inc. (NYSE: EBS) announced [...]
Posted by: fuadelhibri on: November 4, 2010
ROCKVILLE, Md., Oct 28, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the acquisition of Trubion Pharmaceuticals, Inc., following a majority vote to approve the merger by Trubion stockholders at a special meeting conducted at Trubion’s Seattle headquarters on October 28, 2010. The acquisition provides Emergent with multiple, advanced [...]
Posted by: fuadelhibri on: August 19, 2010
Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates Emergent reaffirms 2010 guidance for revenues and net income ROCKVILLE, Md., Aug 12, 2010 (BUSINESS [...]
